Onconetix, Inc., a pharmaceutical company with a market capitalization of just $3.98 million, has received a notification from The Nasdaq Stock Market LLC indicating non-compliance with the minimum ...

Onconetix, Inc. (NASDAQ:ONCO), a pharmaceutical company with a market capitalization of $4.48 million, has reached a settlement agreement with IQVIA, Inc., a provider of advanced analytics ...

Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6 ...

Onconetix, Inc. announced that it received a notice from Nasdaq on December 6, 2024, regarding its failure to file the Quarterly Report on Form 10-Q for the period ending September 30, 2024 ...

EST Onconetix (ONCO) files to sell 50M shares of common stock for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 indicating that the Company’s failure to ...

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians ...

Onconetix, Inc. (NASDAQ:ONCO), a pharmaceutical company with a market capitalization of $4.48 million, has reached a settlement agreement with IQVIA, Inc., a provider of advanced analytics, technology ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 ...